rs8100241
|
USHBP1;ANKLE1
|
Colorectal Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
The variant rs8100241 located in ANKLE1 was significantly associated with CRC risk (odds ratio = 0.88, 95% confidence interval = 0.84-0.92, p = 4.85 × 10<sup>-8</sup> ) in 8,403 cases and 10,086 controls.
|
31509622 |
2019 |
rs2278256
|
BABAM1;USHBP1
|
Triple Negative Breast Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the haplotypes containing two polymorphisms rs7250266 and rs2278256 are associated with a lower chance of TNBC development specifically.
|
26848770 |
2016 |
rs2278256
|
BABAM1;USHBP1
|
Triple-Negative Breast Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the haplotypes containing two polymorphisms rs7250266 and rs2278256 are associated with a lower chance of TNBC development specifically.
|
26848770 |
2016 |
rs7250266
|
BABAM1;USHBP1
|
Triple-Negative Breast Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs7250266 in the promoter region of NBA1 confers a decreased risk to TNBC development, but not to non-TNBC</span> susceptibility.
|
26848770 |
2016 |
rs7250266
|
BABAM1;USHBP1
|
Triple Negative Breast Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs7250266 in the promoter region of NBA1 confers a decreased risk to TNBC development, but not to non-TNBC</span> susceptibility.
|
26848770 |
2016 |
rs8170
|
BABAM1;USHBP1
|
progesterone receptor-negative breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
Index SNPs in five loci were replicated, including three associated with ER-/PR- breast cancer (TERT rs10069690 in 5p15.33, rs704010 in 10q22.3, and rs8170 in 19p13.11): per allele ORs were 1.29 [95% confidence interval (CI) 1.04-1.59], P = 0.02, 1.52 (95% CI 1.12-2.08), P = 0.01, and 1.30 (95% CI 1.01-1.68), P = 0.04, respectively.
|
23136140 |
2013 |
rs8170
|
BABAM1;USHBP1
|
progesterone receptor-positive breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
Index SNPs in five loci were replicated, including three associated with ER-/PR- breast cancer (TERT rs10069690 in 5p15.33, rs704010 in 10q22.3, and rs8170 in 19p13.11): per allele ORs were 1.29 [95% confidence interval (CI) 1.04-1.59], P = 0.02, 1.52 (95% CI 1.12-2.08), P = 0.01, and 1.30 (95% CI 1.01-1.68), P = 0.04, respectively.
|
23136140 |
2013 |
rs8170
|
BABAM1;USHBP1
|
HER2-negative breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10(-5)] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10(-7)).
|
22331459 |
2012 |
rs8170
|
BABAM1;USHBP1
|
Oestrogen receptor positive breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
Variants from 19p13.1 were not associated with breast cancer overall or with ER-positive breast cancer but were significantly associated with ER-negative breast cancer risk [rs8170 OR, 1.10; 95% confidence interval (CI), 1.05-1.15; P = 3.49 × 10(-5)] and triple-negative (ER-, PR-, and HER2-negative) breast cancer (rs8170: OR, 1.22; 95% CI, 1.13-1.31; P = 2.22 × 10(-7)).
|
22331459 |
2012 |
rs8170
|
BABAM1;USHBP1
|
estrogen receptor-negative breast cancer
|
|
0.010 |
GeneticVariation |
BEFREE |
However, rs8170 was no longer associated with ER-negative breast cancer risk when triple-negative cases were excluded (OR, 0.98; 95% CI, 0.89-1.07; P = 0.62).
|
22331459 |
2012 |
rs8100241
|
USHBP1;ANKLE1
|
Triple Negative Breast Neoplasms
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
rs8100241
|
USHBP1;ANKLE1
|
Triple-Negative Breast Carcinoma
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
rs8170
|
BABAM1;USHBP1
|
Carcinoma, Ovarian Epithelial
|
|
0.020 |
GeneticVariation |
BEFREE |
Common variant rs8170 and rare variants in ATG2B may be associated with EOC overall survival, although further study is needed.
|
26747452 |
2016 |
rs8170
|
BABAM1;USHBP1
|
Triple-Negative Breast Carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P = 3.31 × 10(-13)].
|
22331459 |
2012 |
rs8170
|
BABAM1;USHBP1
|
Triple Negative Breast Neoplasms
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P = 3.31 × 10(-13)].
|
22331459 |
2012 |
rs8170
|
BABAM1;USHBP1
|
Triple Negative Breast Neoplasms
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
rs8170
|
BABAM1;USHBP1
|
Triple-Negative Breast Carcinoma
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
rs8170
|
BABAM1;USHBP1
|
Carcinoma, Ovarian Epithelial
|
|
0.020 |
GeneticVariation |
BEFREE |
Expression analysis of candidate genes at this locus in ovarian tumors supported a role for the BRCA1-interacting gene C19orf62, also known as MERIT40, which contains rs8170, in EOC development.
|
20852633 |
2010 |
rs4808075
|
BABAM1;USHBP1
|
Ovarian Serous Adenocarcinoma
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
|
28346442 |
2017 |
rs4808075
|
BABAM1;USHBP1
|
ovarian neoplasm
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.
|
28346442 |
2017 |
rs4808075
|
BABAM1;USHBP1
|
Prostate carcinoma
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
rs4808075
|
BABAM1;USHBP1
|
COLORECTAL CANCER, SUSCEPTIBILITY TO, 1
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
rs4808075
|
BABAM1;USHBP1
|
Ovarian Serous Adenocarcinoma
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
rs4808075
|
BABAM1;USHBP1
|
Endometrioid carcinoma ovary
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |
rs4808075
|
BABAM1;USHBP1
|
Malignant neoplasm of large intestine
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.
|
27197191 |
2016 |